Automated Imaging Differentiation of Parkinsonism (AIDP)

The purpose of this study is to test the performance of the AID-P across 21 sites in the Parkinson Study Group. Each site will perform imaging, clinical scales, diagnosis, and will upload the data to the web-based software tool. The clinical diagnosis will be blinded to the diagnostic algorithm and the imaging diagnosis will be compared to the movement disorders trained neurologist diagnosis.

Study Overview

• Status: Active, not recruiting
• Conditions: Parkinson Disease; Progressive Supranuclear Palsy; Multiple System Atrophy, Parkinson Variant
• Intervention / Treatment: Diagnostic test: AIDP

• Study Type: Observational
• Enrollment (Estimated): 315

Contacts and Locations

Study Locations

• Canada
  • Ottawa, Canada, K1Y 4E9
    • Ottawa Hospital Research Institute
  • Toronto, Canada, M5T 2S8
    • Centre for Addiction and Mental Health
• United States
  • Alabama
    • Birmingham, Alabama, United States, 35294
      • University of Alabama at Birmingham
  • California
    • La Jolla, California, United States, 92037
      • University of California San Diego
    • San Francisco, California, United States, 94158
      • University of California San Francisco
  • Florida
    • Gainesville, Florida, United States, 32611
      • University of Florida
    • Tampa, Florida, United States, 33613
      • University of South Florida
  • Georgia
    • Augusta, Georgia, United States, 30912
      • Augusta University
  • Illinois
    • Chicago, Illinois, United States, 60611
      • Northwestern University
    • Chicago, Illinois, United States, 60637
      • University of Chicago
  • Kentucky
    • Lexington, Kentucky, United States, 40536
      • University of Kentucky
  • Maryland
    • Lutherville, Maryland, United States, 21093
      • Johns Hopkins University
  • Massachusetts
    • Boston, Massachusetts, United States, 02215
      • Beth Israel Deaconess Medical Center
    • Charlestown, Massachusetts, United States, 02129
      • Massachusetts General Hospital
  • Michigan
    • Ann Arbor, Michigan, United States, 48106
      • University of Michigan
  • Minnesota
    • Minneapolis, Minnesota, United States, 55414
      • University of Minnesota
  • Missouri
    • St Louis, Missouri, United States, 63110
      • Washington University in St. Louis
  • New York
    • Albany, New York, United States, 12020
      • Albany Medical College
  • North Carolina
    • Durham, North Carolina, United States, 22705
      • Duke University Medical Center
    • Winston-Salem, North Carolina, United States, 27157
      • Wake Forest University
  • Pennsylvania
    • Hershey, Pennsylvania, United States, 17033
      • Pennsylvania State University

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Adults between the ages of 40 and 80 who meet one of the three diagnoses: PD, MSAp, or PSP

*As of 11/9/23, we have filled the cohorts for both PD and PSP patients. We are only enrolling MSAp patients at this time.

Description

Inclusion Criteria:

• Parkinson's disease diagnosis within 5-9 years of baseline date
• MSAp diagnosis
• PSP diagnosis

Exclusion Criteria:

• metal implants in the body that preclude an MRI (pacemaker, metallic clip, neurostimulator, etc)
• claustrophobia
• pregnancy

Study Plan

How is the study designed?

Number of groups / cohorts

3

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Parkinson's disease; Clinically diagnosed Parkinson's disease	Diagnostic test: AIDP; Machine learning algorithm of imaging data
Multiple System Atrophy, Parkinsonian variant; Clinically diagnosed Multiple System Atrophy, Parkinsonian variant	Diagnostic test: AIDP; Machine learning algorithm of imaging data
Progressive Supranuclear Palsy; Clinically diagnosed Progressive Supranuclear Palsy	Diagnostic test: AIDP; Machine learning algorithm of imaging data

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Predicted diagnosis accuracy	utilizing the automated imaging differentiation of Parkinsonism (AIDP) tool to predict diagnosis compared to the expertise of two movement disorder specialists	12-18 months

Collaborators and Investigators

• Sponsor: University of Florida
• Collaborators: Johns Hopkins University; Massachusetts General Hospital; Washington University School of Medicine; University of California, San Diego; University of South Florida; Northwestern University; Centre for Addiction and Mental Health; Beth Israel Deaconess Medical Center; University of Alabama at Birmingham; University of Chicago; National Institute of Neurological Disorders and Stroke (NINDS); University of Michigan; Duke University; University of California, San Francisco; Ottawa Hospital Research Institute; University of Minnesota; Penn State University; Augusta University; University of Kentucky; Albany Medical College; Wake Forest University

Study record dates

Study Major Dates

• Study Start (Actual): July 22, 2021
• Primary Completion (Estimated): March 31, 2026
• Study Completion (Estimated): March 31, 2026

Study Registration Dates

• First Submitted: June 13, 2023
• First Submitted That Met QC Criteria: June 13, 2023
• First Posted (Actual): June 22, 2023

Study Record Updates

• Last Update Posted (Estimated): January 16, 2026
• Last Update Submitted That Met QC Criteria: January 15, 2026
• Last Verified: October 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Synucleinopathies; Neurologic Manifestations; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Eye Diseases; Tauopathies; Neurodegenerative Diseases; Movement Disorders; Parkinsonian Disorders; Basal Ganglia Diseases; Cranial Nerve Diseases; Primary Dysautonomias; Autonomic Nervous System Diseases; Ophthalmoplegia; Ocular Motility Disorders; Paralysis; Pathological Conditions, Signs and Symptoms; Signs and Symptoms; Parkinson Disease; Multiple System Atrophy; Supranuclear Palsy, Progressive
• Other Study ID Numbers: IRB202002350; PRO00028349 (Other Identifier: UF); 5U01NS119562 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No